Drugs / CART-EGFR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01869166 | May 2013 → Dec 2016 | — | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR T-EGFR | “We conducted a phase I clinical trial to evaluate the safety and efficacy of autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells in patients with metastatic PC.” PMID 32527643 ↗ Jun 2020 |
| Action | Deplete | “Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous T cells may make the body build immune response to kill cancer cells.” NCT01869166 ↗ |
| Modality | Cell therapy | “autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells” PMID 32527643 ↗ Jun 2020 |